BioWorld

June 17, 2002

View Archived Issues

FDA Asks Biogen To Clarify Info On Amevive, But No Trial Needed

The FDA's positive feedback on Biogen Inc.'s Amevive application likely will be the first in a series of key events expected to drive the biotechnology industry this year, an analyst said.(BioWorld Today) Read More

SciClone Gets $10.6M 'Insurance' Financing To Advance Zadaxin

Read More

Air Strikes, Not Ground Attacks, To Destroy Immune Cytokines Of Lethal Graft-Versus-Host Disease

Read More

Abbott Reports Positive Data From Anti-TNF RA Antibody

Read More

Other News To Note

Read More

Appointments And Advancements

Read More